Literature DB >> 28339283

Development, optimization and implementation of a centralized metabolic soft spot assay.

Anthony A Paiva1, Cheryl Klakouski2, Shu Li1, Benjamin M Johnson2, Yue-Zhong Shu3, Jonathan Josephs4,5, Tatyana Zvyaga1, Ismael Zamora6, Wilson Z Shou1.   

Abstract

AIM: High clearance is a commonly encountered issue in drug discovery. Here we present a centralized metabolic soft spot identification assay with adequate capacity and turnaround time to support the metabolic optimization needs of an entire discovery organization.
METHODOLOGY: An integrated quan/qual approach utilizing both an orthogonal sample-pooling methodology and software-assisted structure elucidation was developed to enable the assay. Major metabolic soft spots in liver microsomes (rodent and human) were generated in a batch mode, along with kinetics of parent disappearance and metabolite formation, typically within 1 week of incubation. RESULTS &
CONCLUSION: A centralized metabolic soft spot identification assay has been developed and has successfully impacted discovery project teams in mitigating instability and establishing potential structure-metabolism relationships.

Entities:  

Keywords:  dual-concentration incubation; metabolic soft spot; metabolic stability; orthogonal sample pooling; software assisted data processing

Mesh:

Year:  2017        PMID: 28339283     DOI: 10.4155/bio-2016-0299

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  5 in total

1.  Discovery of Pyridazinone and Pyrazolo[1,5-a]pyridine Inhibitors of C-Terminal Src Kinase.

Authors:  Daniel P O'Malley; Vijay Ahuja; Brian Fink; Carolyn Cao; Cindy Wang; Jesse Swanson; Susan Wee; Ashvinikumar V Gavai; John Tokarski; David Critton; Anthony A Paiva; Benjamin M Johnson; Nicolas Szapiel; Dianlin Xie
Journal:  ACS Med Chem Lett       Date:  2019-09-25       Impact factor: 4.345

2.  Software-aided approach to investigate peptide structure and metabolic susceptibility of amide bonds in peptide drugs based on high resolution mass spectrometry.

Authors:  Tatiana Radchenko; Andreas Brink; Yves Siegrist; Christopher Kochansky; Alison Bateman; Fabien Fontaine; Luca Morettoni; Ismael Zamora
Journal:  PLoS One       Date:  2017-11-01       Impact factor: 3.240

Review 3.  Current status and future directions of high-throughput ADME screening in drug discovery.

Authors:  Wilson Z Shou
Journal:  J Pharm Anal       Date:  2020-05-23

Review 4.  Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae.

Authors:  Nils Ohnesorge; Temitope Sasore; Daniel Hillary; Yolanda Alvarez; Michelle Carey; Breandán N Kennedy
Journal:  Front Pharmacol       Date:  2019-05-24       Impact factor: 5.810

5.  Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications.

Authors:  Laura Goracci; Jenny Desantis; Aurora Valeri; Beatrice Castellani; Michela Eleuteri; Gabriele Cruciani
Journal:  J Med Chem       Date:  2020-10-07       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.